Trial · NCT00685945

Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3

NCT00685945, Not applicable, Completed, Vanderbilt University; results first posted 2013-02-25

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3. Trials, record NCT00685945. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00685945

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Renin-Angiotensin Aldosterone System and Fibrinolysis Interaction in Humans-Specific Aim 3
NCT number: NCT00685945
Status: Completed
Phases: Not applicable
Enrollment: 24 participants, actual
Lead sponsor: Vanderbilt University
Conditions: Obesity
Interventions: Control (bradykinin), L-NMMA + bradykinin, Isosorbide + L-NMMA + bradykinin, Sildenafil + L-NMMA + bradykinin
First posted: 2008-05-29
Last updated: 2013-02-25
Results first posted: 2013-02-25

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Net Tissue-type Plasminogen Activator (t-PA) Release	During and after each study drug administration	Individual net t-PA release at each time point were calculated by the following formula: net release = (Cv-CA) x {FBF x \[101-hematocrit/100\]}, where Cv and CA represent the concentration of t-PA in the brachial vein and artery, respectively.
Secondary	Forearm Blood Flow (FBF)	During and after each study drug administration	Forearm blood flow was measured by strain gauge plethysmography
Other	Net Glucose Uptake	At baseline and after maximum dose of bradykinin	Individual net reuptake rates at each time point were calculated by the following formula: net uptake = (Cv-CA) x {FBF x \[101-hematocrit/100\]}, where Cv and CA represent the concentration of glucose in the brachial vein and artery, respectively.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Net Tissue-type Plasminogen Activator (t-PA) Release	During and after each study drug administration	Twenty four subjects were studied. One subject was excluded because of erroneous drug administration. Analysis was per protocol. Twenty-three subjects receive bradykinin then L-NMMA plus bradykinin infusions. Subjects were then randomized to either isosorbide or sildenafil. Twelve subjects received sildenafil and 11 subjects received isosorbide.	ng/min/100ml	MEAN
SECONDARY	Forearm Blood Flow (FBF)	During and after each study drug administration		ml/min/100ml	MEAN
OTHER_PRE_SPECIFIED	Net Glucose Uptake	At baseline and after maximum dose of bradykinin		microgram/min/100ml	MEAN

Source ClinicalTrials.gov

Results by group40

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Net Tissue-type Plasminogen Activator (t-PA) Release	Control	Net t-PA release (bradykinin 0ng/min)	0.24	Standard Error 0.39	ng/min/100ml
Net Tissue-type Plasminogen Activator (t-PA) Release	L-NMMA + Control	Net t-PA release (bradykinin 0ng/min)	0.59	Standard Error 0.23	ng/min/100ml
Net Tissue-type Plasminogen Activator (t-PA) Release	Isosorbide + L-NMMA + Control	Net t-PA release (bradykinin 0ng/min)	-0.38	Standard Error 0.51	ng/min/100ml
Net Tissue-type Plasminogen Activator (t-PA) Release	Sildenafil + L-NMMA + Control	Net t-PA release (bradykinin 0ng/min)	0.29	Standard Error 0.67	ng/min/100ml
Net Tissue-type Plasminogen Activator (t-PA) Release	Control	Net t-PA release (bradykinin 50ng/min)	1.02	Standard Error 1.06	ng/min/100ml
Net Tissue-type Plasminogen Activator (t-PA) Release	L-NMMA + Control	Net t-PA release (bradykinin 50ng/min)	3.65	Standard Error 0.79	ng/min/100ml
Net Tissue-type Plasminogen Activator (t-PA) Release	Isosorbide + L-NMMA + Control	Net t-PA release (bradykinin 50ng/min)	3.14	Standard Error 1.13	ng/min/100ml
Net Tissue-type Plasminogen Activator (t-PA) Release	Sildenafil + L-NMMA + Control	Net t-PA release (bradykinin 50ng/min)	2.46	Standard Error 2.07	ng/min/100ml
Net Tissue-type Plasminogen Activator (t-PA) Release	Control	Net t-PA release (bradykinin 100ng/min)	11.81	Standard Error 2.12	ng/min/100ml
Net Tissue-type Plasminogen Activator (t-PA) Release	L-NMMA + Control	Net t-PA release (bradykinin 100ng/min)	22.10	Standard Error 5.51	ng/min/100ml

1 to 10 of 40Source ClinicalTrials.gov

See all 40 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Control (Bradykinin Infusion)	STARTED	All Participants	24
Control (Bradykinin Infusion)	COMPLETED	All Participants	24
Control (Bradykinin Infusion)	NOT COMPLETED	All Participants	0
L-NMMA + Bradykinin	STARTED	All Participants	24
L-NMMA + Bradykinin	COMPLETED	All Participants	23
L-NMMA + Bradykinin	NOT COMPLETED	All Participants	1
Isosorbide + L-NMMA + Bradykinin	STARTED	All Participants	11
Isosorbide + L-NMMA + Bradykinin	COMPLETED	All Participants	11
Isosorbide + L-NMMA + Bradykinin	NOT COMPLETED	All Participants	0
Sildenafil + L-NMMA + Bradykinin	STARTED	All Participants	12

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events3

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Headache	Nervous system disorders	All Participants	2	24	2
other	fainted	Nervous system disorders	All Participants	1	24	1
other	unexpected drug response	Vascular disorders	All Participants	1	24	1

Source ClinicalTrials.gov

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	All Participants
Total, other adverse events	All Participants	4	24
Total, serious adverse events	All Participants	0	24

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
19841473	RESULT

Source PubMed

Grants3

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years	Source
R01HL060906	Renin-Angiotensin & Fibrinolysis Interaction in Humans	BROWN, NANCY J.	VANDERBILT UNIVERSITY	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE	1998 to 2014	NIH RePORTER
UL1RR024975	The Vanderbilt Institute for Clinical and Translational Research (VICTR) UL1	BERNARD, GORDON RAPHAEL	VANDERBILT UNIVERSITY	NATIONAL CENTER FOR RESEARCH RESOURCES	2007 to 2011	NIH RePORTER
R01HL085740	Bradykinin Receptor Antagonism During Cardiopulmonary Bypass	PRETORIUS, MIAS	VANDERBILT UNIVERSITY	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE	2006 to 2010	NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00685945

GET https://conductscience.org/api/trials/v1/NCT00685945/results?page=2

API reference For AI assistants